NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience’s proposed product in Canada until Pfizer’s amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appeal of Canada.
